Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uhi Toh

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|October 24, 2023
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancerTakayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.
Molecular and Clinical Oncology|March 21, 2014
FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosisMiki Takenaka, Naoko Seki, Uhi Toh, et al.
Breast Cancer (Tokyo, Japan)|April 3, 2021
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)Manabu Futamura, Mari Oba, Norikazu Masuda, et al.
International Journal of Oncology|April 3, 2020
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patientsShigetaka Suekane, Shigeru Yutani, Akira Yamada, et al.
Breast Cancer (Tokyo, Japan)|July 28, 2020
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) studyYutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer (Tokyo, Japan)|May 25, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational studyShigeru Imoto, Hiroyuki Yasojima, Takeshi Nagashima, et al.
The Lancet. Oncology|April 11, 2022
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trialShigehira Saji, Naruto Taira, Masahiro Kitada, et al.
Breast Cancer Research : BCR|May 29, 2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort studyTakashi Ishikawa, Yukari Uemura, Hirohito Seki, et al.
Cancer Biology & Therapy|October 12, 2010
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccinationMasanori Noguchi, Takashi Mine, Nobukazu Komatsu, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|October 24, 2023
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancerTakayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.
Molecular and Clinical Oncology|March 21, 2014
FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosisMiki Takenaka, Naoko Seki, Uhi Toh, et al.
Breast Cancer (Tokyo, Japan)|April 3, 2021
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)Manabu Futamura, Mari Oba, Norikazu Masuda, et al.
International Journal of Oncology|April 3, 2020
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patientsShigetaka Suekane, Shigeru Yutani, Akira Yamada, et al.
Breast Cancer (Tokyo, Japan)|July 28, 2020
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) studyYutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer (Tokyo, Japan)|May 25, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational studyShigeru Imoto, Hiroyuki Yasojima, Takeshi Nagashima, et al.
The Lancet. Oncology|April 11, 2022
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trialShigehira Saji, Naruto Taira, Masahiro Kitada, et al.
Breast Cancer Research : BCR|May 29, 2026
Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort studyTakashi Ishikawa, Yukari Uemura, Hirohito Seki, et al.
Cancer Biology & Therapy|October 12, 2010
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccinationMasanori Noguchi, Takashi Mine, Nobukazu Komatsu, et al.
Pageof 7